Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Duke University |
---|---|
Information provided by: | Duke University |
ClinicalTrials.gov Identifier: | NCT00615121 |
Peripheral artery disease is a disease that contributes to significant morbidity and mortality of millions of Americans yearly. Very little is known about the pathophysiology of atherosclerosis in peripheral artery disease. We plan to collect peripheral arteries from patients undergoing amputation for end stage peripheral arterial occlusive disease. By extracting the RNA from these arteries and comparing them with RNA expression from normal arteries, we hope to have a better understanding of the pathophysiology of atherosclerosis in this setting. We aim to prove the hypothesis that a novel gene expression pattern can be discovered by the successful extraction of RNA from plaques from human peripheral arteries.
Condition |
---|
Peripheral Artery Disease |
Study Type: | Observational |
Study Design: | Case Control, Cross-Sectional |
Official Title: | Genetics of Peripheral Artery Disease |
Peripheral artery samples collected from patients are stored in -80celcius refrigerator for future analysis.
Estimated Enrollment: | 100 |
Study Start Date: | June 2004 |
Estimated Study Completion Date: | July 2009 |
Estimated Primary Completion Date: | June 2009 (Final data collection date for primary outcome measure) |
Groups/Cohorts |
---|
1
peripheral arteries from patients undergoing amputation for end stage peripheral arterial occlusive disease
|
2
peripheral arteries from patients without evidence of peripheral arterial occlusive disease
|
Patients scheduled to undergo lower extremity amputation will be consented for extraction of plaque from the carotid artery or arterial tissue from the amputated limbs. The surgeon will perform the amputation, then the harvest team will collect arterial tissue from amputated limbs. These samples will be immersed in RNALater solution to preserve the integrity of the RNA. Tissues will stored at -80oC in the RNALater until the RNA is later extracted using a standardized protocol. The RNA will be examined for quality using an Agilent bioanalyzer, and will then be processed on Affymetrix U133A chips for gene expression data. The data will be analyzed with the MATLAB software package.
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Non-Probability Sample |
Patients with peripheral artery occlusive disease.
Inclusion Criteria:
Exclusion Criteria:
Contact: Bantayehu Sileshi, MD | (919) 668-6112 | bantayehu.sileshi@duke.edu |
Contact: Suzanne Finley | (919) 681-1093 | finle008@mc.duke.edu |
United States, North Carolina | |
Duke University Medical Center | Recruiting |
Durham, North Carolina, United States, 27710 | |
Principal Investigator: Jeffrey H Lawson, MD, PhD |
Principal Investigator: | Jeffrey H Lawson, MD, PhD | Duke University |
Responsible Party: | Duke University Medical Center ( Jeffrey H. Lawson, MD, Ph.D ) |
Study ID Numbers: | 4814-07 |
Study First Received: | February 3, 2008 |
Last Updated: | February 3, 2008 |
ClinicalTrials.gov Identifier: | NCT00615121 |
Health Authority: | United States: Institutional Review Board |
Smoking Hypertension Diabetes Cardiovascular disease Renal Failure |
Smoking Diabetes Mellitus Hypertension Kidney Failure |